Four Oncology Drugs Face FDA PDUFA Decisions in 2026, Stacking Binary Catalyst Risk Into a Narrow Window
Ifinatamab Deruxtecan, Ziihera, Tecentriq, and Gedatolisib all face FDA approval decisions in mid-to-late 2026, compressing binary outcome risk into a dense calendar window for oncology biotech investors. Next-generation modalities — including iPSC-derived cell therapies and bispecific antibodies — extend the catalyst thesis into Q1 2027. Venetoclax-based CLL data presented at EHA 2026 reinforces the durability case for combination regimens now in regulatory review.
Salvado•